NASDAQ · STOCK
Bio-Rad Laboratories
$325.52
52W $236.73 – $343.12
52/100
$8.80B
53.3
1.08
Is BIO Bullish or Bearish?
Mixed.
Innellis AI committee rates Bio-Rad Laboratories (BIO) Watch with a composite score of 52/100
, based on 7 analysts with 71% agreement.
Last updated July 31, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +8.15 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -11.85 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.17 across 6 articles, 14d). Growth Analyst remains cautious — 2 consecutive earnings misses -- execution concerns. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Low leverage (debt-to-equity 0.16) -- balance sheet can absorb a shock — Risk
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- P/E of 51.8 is expensive by classic value standards — Value
- ROE of only 2.4% -- cheap may mean cheap for a reason — Value
- 2 consecutive earnings misses -- execution concerns — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- RSI at 74 is in overbought territory — Technical
- Bollinger bandwidth of 16.8% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 31, 2026
Overall Committee Score
52/100
Agreement
71%
Analysts
7
Conviction
Moderate
Sector Rank
Top 76%
of 93 Healthcare peers
Value Analyst
neutral
50
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ Price-to-book of 1.1x is a discount to asset value
− P/E of 51.8 is expensive by classic value standards
Growth Analyst
bearish
32
/ 100 · High confidence
Growth story is weak, decelerating, or inconsistent
− 2 consecutive earnings misses -- execution concerns
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 74 is in overbought territory
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.16) -- balance sheet can absorb a shock
− Bollinger bandwidth of 16.8% signals elevated volatility
Macro Analyst
neutral
58
/ 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
63
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.17 across 6 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Investment Thesis Evolution
Committee score moved marginally from 52.9 to 51.9.
- Conviction changed from contested to moderate.
- Committee agreement increased notably from 57% to 71%.
- New bearish signals: 4 appeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 4 signal(s) disappeared.
- Analyst(s) changed stance: Macro Analyst.
Analyst-level changes:
- Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
- Portfolio Manager: +2 bearish signal(s).
- Risk Analyst: +1 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-07-30 to 2026-07-31 (1 day apart).
Technical Analysis
RSI (14)
70.8
Overbought
MACD Histogram
2.327
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$309.37
Resistance
$328.12
Bollinger %B
0.85
Inside Bands
Price vs Moving Averages
EMA 9
$319.33
Above
EMA 21
$309.76
Above
EMA 50
$299.31
Above
EMA 200
$290.82
Above
Fundamental Analysis
Valuation
67
Growth
49
Profitability
0
Financial Health
100
Cash Flow
37
Valuation
P/E Ratio
53.3×
P/B Ratio
1.28×
PEG Ratio
-0.13
Dividend Yield
0.00%
52W High
$343.12
52W Low
$236.73
Quality & Growth
ROE
10.2%
ROA
7.2%
Gross Margin
51.9%
Operating Margin
9.2%
Revenue Growth YoY
—
Debt / Equity
0.20
AI Fundamental Assessment
P/E ratio of 53.3 (rich relative to a 15-40x range); Price-to-book of 1.3x; PEG ratio of -0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.1%; Net margin of 0.1%; Gross margin of 0.5%; Current ratio of 3.21 (healthy short-term liquidity); Debt-to-equity of 0.20; Free cash flow margin of 0.7% (thin cash generation); Free cash flow per share is positive (13.25); Most recent quarter missed estimates by 5.7%; 2 consecutive earnings misses; EPS growth decelerating (+11.1% -> -24.7% QoQ); Analyst estimates rising over recent quarters
Get the Full BIO Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →